Effects of Autoimmune Disorders on Myelodysplastic Syndrome Outcomes: A Systematic Review
Issued Date
2024-06-01
Resource Type
eISSN
26736357
Scopus ID
2-s2.0-85196768426
Journal Title
Hemato
Volume
5
Issue
2
Start Page
208
End Page
219
Rights Holder(s)
SCOPUS
Bibliographic Citation
Hemato Vol.5 No.2 (2024) , 208-219
Suggested Citation
Saowapa S., Polpichai N., Tanariyakul M., Suenghataiphorn T., Kulthamrongsri N., McCullough M., Damasceno Moreira M.G., Siladech P., Tijani L. Effects of Autoimmune Disorders on Myelodysplastic Syndrome Outcomes: A Systematic Review. Hemato Vol.5 No.2 (2024) , 208-219. 219. doi:10.3390/hemato5020017 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/99247
Title
Effects of Autoimmune Disorders on Myelodysplastic Syndrome Outcomes: A Systematic Review
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: Autoimmune disorders (ADs) are prevalent among patients with myelodysplastic syndrome (MDS), yet their impact on MDS outcomes, including overall survival (OS), mortality, and transformation to acute myeloid leukemia (AML), is not well defined. Methods: We conducted a systematic review of articles published up to April 2024, sourced from PubMed, Web of Science, Embase, and Google Scholar, focusing on the influence of ADs on survival and AML transformation rates in MDS patients. The methodological quality of each study was assessed using the Newcastle Ottawa Scale. Results: From 8 studies that met the inclusion criteria, ADs were present in 17.5% (3074/17,481) of MDS patients. Data analysis indicated mortality rates ranging from 15.3% to 67% in MDS patients with ADs and 12% to 69% in those without. The rate of AML transformation varied from 0% to 23% in patients with ADs compared to 4% to 30% in those without. Conclusions: The influence of ADs on survival and AML transformation in MDS patients appears variable. This systematic review highlights the need for further large-scale prospective studies to clarify the relationship between ADs and MDS outcomes.